Speaker: Associate Professor Billingsley Kaambwa, Head of the Health Economics Unit, School of Medicine, Flinders University of South Australia.
Title: Is the use of high-sensitivity troponin among patients presenting with undifferentiated chest pain cost-effective? Results from an economic evaluation conducted alongside a randomised controlled trial.
Chair: Dr Isuru Ranasinghe, National Heart Foundation Future Leader Fellow, Health Performance and Policy Research Unit, Basil Hetzel Institute and University of Adelaide. Located ground floor BHI, TQEH. [email protected]
Speaker biopgrahy: Associate Professor Billingsley (Billy) Kaambwa heads the Health Economics Unit at Flinders University. In addition to a BA in Economics and Statistics and an MA in Health Economics, he holds a PhD in Health Economics & Statistics (University of Birmingham, UK). Billingsley has also had advanced training in applied epidemiology and statistics at the Universities of Cambridge and Michigan. He has over 15 years’ experience in health economics research in Australian and the UK. He has published in leading international peer-reviewed journals for both methodological (e.g. PharmacoEconomics, Value in Health, Quality of Life Research, BMC series) and applied (e.g. The Lancet, International Journal of Cardiology, European Journal of Health Economics) work. He has been a co-applicant on successful grant applications that total more than $13.8 million. His main research interests are in the application of econometric and statistical techniques in economic evaluation, decision analytic modelling and economic evaluation of new and existing health care technologies. He has substantial expertise in the use of both short-term and long-term economic evaluation modelling techniques. Billingsley’s research encompasses a number of clinical areas ranging from public health to management of chronic conditions.